Inotiv, Inc. Announces Preliminary Fiscal 2025 Fourth Quarter and Full Year Results

Preliminary Expected Fourth Quarter 2025 Revenue of $137.5 to $138.5 Million
Preliminary Expected Full Year 2025 Revenue of $512.5 to $513.5 Million

Updated Time of Company Presentation at Jefferies Global Healthcare Conference  

WEST LAFAYETTE, Ind., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced select preliminary financial results for the fourth quarter (“Q4 FY 2025”) and full year (“FY 2025”) ended September 30, 2025.

Robert Leasure Jr., President and Chief Executive Officer, commented, “During the fourth quarter of fiscal 2025, we continued to execute on the financial goals we discussed during our investor day in May. We have continued to see strong contract awards in our Discovery and Safety Assessment (“DSA”) services business, which grew sequentially in the fourth quarter and were up 60% over the same period last year. We anticipate that consolidated revenue for the fourth quarter will be in a range of $137.5 million to $138.5 million, in line with our expectations and an improvement over the prior year period. We look forward to reporting our full results for the fourth quarter and fiscal year 2025 in early December.”

Preliminary Fourth Quarter 2025 Highlights

• Anticipate revenue between $137.5 million and $138.5 million for Q4 FY 2025
• Book-to-bill ratio for Q4 FY 2025 is anticipated to be approximately 1.08x for the DSA services business
• Anticipated DSA backlog of approximately $138.0 million at September 30, 2025, compared to $129.9 million at September 30, 2024, and $134.3 million at June 30, 2025
  

Preliminary FY 2025 Highlights

• Anticipate revenue between $512.5 million and $513.5 million for FY 2025
• Book-to-bill ratio for FY 2025 is anticipated to be approximately 1.05x for the DSA services business

The preliminary, unaudited results described in this press release are estimates only and are subject to change in connection with the completion of the Company’s year-end accounting and financial reporting and audit procedures.

Updated Jefferies Conference Details

The Company also announced an updated time for Mr. Leasure’s presentation at the Jefferies Global Healthcare Conference, to be held in London, UK, this week, as follows: